330 related articles for article (PubMed ID: 21784892)
41. Membranous nephropathy with light chain restricted deposits.
Ramachandran R; Inamdar N; Bharati J; Yadav AK; Kumar A; Prakash G; Nada R; Rathi M; Kohli HS; Gupta KL; Jha V
Nephrology (Carlton); 2018 Aug; 23(8):791-796. PubMed ID: 29633425
[TBL] [Abstract][Full Text] [Related]
42. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.
Stehlé T; Audard V; Ronco P; Debiec H
Nephrol Dial Transplant; 2015 Jun; 30(6):1047-50. PubMed ID: 25839741
[TBL] [Abstract][Full Text] [Related]
43. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.
Fresquet M; Jowitt TA; Gummadova J; Collins R; O'Cualain R; McKenzie EA; Lennon R; Brenchley PE
J Am Soc Nephrol; 2015 Feb; 26(2):302-13. PubMed ID: 25288605
[TBL] [Abstract][Full Text] [Related]
44. Molecular classification of membranous nephropathy.
Pozdzik A; Touzani F; Brochériou I; Corazza F
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):336-344. PubMed ID: 31045661
[TBL] [Abstract][Full Text] [Related]
45. PLA2R related primary membranous nephropathy in a hepatitis C positive patient.
Ramachandran R; Yadav AK; Kumar V; Varma A; Taneja S; Nada R; Gupta KL; Jha V
Nephrology (Carlton); 2018 Mar; 23(3):288. PubMed ID: 29460999
[No Abstract] [Full Text] [Related]
46. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
Segarra-Medrano A; Jatem-Escalante E; Carnicer-Cáceres C; Agraz-Pamplona I; Salcedo MT; Valtierra N; Ostos-Roldán E; Arredondo KV; Jaramillo J
Nefrologia; 2014; 34(4):491-7. PubMed ID: 25036063
[TBL] [Abstract][Full Text] [Related]
47. Detection and monitoring PLA
Burbelo PD; Beck LH; Waldman M
J Immunol Methods; 2017 May; 444():17-23. PubMed ID: 28167276
[TBL] [Abstract][Full Text] [Related]
48. Factor H Autoantibodies and Membranous Nephropathy.
Seikrit C; Ronco P; Debiec H
N Engl J Med; 2018 Dec; 379(25):2479-2481. PubMed ID: 30575481
[No Abstract] [Full Text] [Related]
49. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
Barrett C; Willcocks LC; Jones RB; Tarzi RM; Henderson RB; Cai G; Gisbert SI; Belson AS; Savage CO
Nephrol Dial Transplant; 2020 Apr; 35(4):599-606. PubMed ID: 31243451
[TBL] [Abstract][Full Text] [Related]
50. Complement activation products in the circulation and urine of primary membranous nephropathy.
Zhang MF; Huang J; Zhang YM; Qu Z; Wang X; Wang F; Meng LQ; Cheng XY; Cui Z; Liu G; Zhao MH
BMC Nephrol; 2019 Aug; 20(1):313. PubMed ID: 31399080
[TBL] [Abstract][Full Text] [Related]
51. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy.
Timmermans SA; Ayalon R; van Paassen P; Beck LH; van Rie H; Wirtz JJ; Verseput GH; Frenken LA; Salant DJ; Cohen Tervaert JW;
Am J Kidney Dis; 2013 Dec; 62(6):1223-5. PubMed ID: 24021909
[No Abstract] [Full Text] [Related]
52. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy.
Ronco P; Debiec H
Nephron Clin Pract; 2014; 128(3-4):232-7. PubMed ID: 25401774
[TBL] [Abstract][Full Text] [Related]
53. Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy.
Kim YG; Choi YW; Kim SY; Moon JY; Ihm CG; Lee TW; Jeong KH; Yang SH; Kim YS; Oh YJ; Lee SH
Am J Nephrol; 2015; 42(3):250-7. PubMed ID: 26484659
[TBL] [Abstract][Full Text] [Related]
54. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.
Dähnrich C; Komorowski L; Probst C; Seitz-Polski B; Esnault V; Wetzels JF; Hofstra JM; Hoxha E; Stahl RA; Lambeau G; Stöcker W; Schlumberger W
Clin Chim Acta; 2013 Jun; 421():213-8. PubMed ID: 23541686
[TBL] [Abstract][Full Text] [Related]
55. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.
Ramachandran R; Kumar V; Nada R; Jha V
Kidney Int; 2015 Nov; 88(5):1198-9. PubMed ID: 26579688
[No Abstract] [Full Text] [Related]
56. Successful Treatment of Patients With Refractory PLA
Klomjit N; Fervenza FC; Zand L
Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
[TBL] [Abstract][Full Text] [Related]
57. [Autoantibodies in membranous nephropathy].
Maruyama S; Akiyama S
Nihon Jinzo Gakkai Shi; 2014; 56(4):486-92. PubMed ID: 24956880
[No Abstract] [Full Text] [Related]
58. Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.
Škoberne A; Behnert A; Teng B; Fritzler MJ; Schiffer L; Pajek J; Lindič J; Haller H; Schiffer M
Eur J Clin Invest; 2014 Aug; 44(8):753-65. PubMed ID: 24942189
[TBL] [Abstract][Full Text] [Related]
59. Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy.
Mella A; Deambrosis I; Mingozzi S; Colla L; Burdese M; Giaretta F; Bruno S; Camussi G; Boaglio E; Dolla C; Clari R; Biancone L
Sci Rep; 2020 Oct; 10(1):16362. PubMed ID: 33004982
[TBL] [Abstract][Full Text] [Related]
60. Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy.
Debiec H; Ronco P
Nat Rev Nephrol; 2011 Aug; 7(9):496-8. PubMed ID: 21826078
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
